#1 Clinical Trials Search in Europe

Oseltamivir

This article summarizes key findings from clinical trials investigating the use of oseltamivir (Tamiflu) for treating influenza in various patient populations. The trials examined aspects such as dosing, safety, pharmacokinetics, and efficacy in groups including children, obese adults, and immunocompromised patients.

Table of Contents

What is Oseltamivir?

Oseltamivir, also known by the brand name Tamiflu, is an antiviral medication used to treat and prevent influenza, commonly known as the flu[1]. It belongs to a class of drugs called neuraminidase inhibitors, which work by blocking the action of a viral enzyme called neuraminidase[3].

How Oseltamivir Works

When you take oseltamivir, your body converts it into an active form called oseltamivir carboxylate[2]. This active form interferes with the flu virus’s ability to spread within your body. By doing so, it can help reduce the severity of flu symptoms and shorten the duration of the illness[3].

Uses of Oseltamivir

Oseltamivir is primarily used for:

  • Treatment of influenza: It can be used to treat both seasonal flu and pandemic flu strains, including H1N1 (swine flu)[3].
  • Prevention of influenza: It may be prescribed to prevent flu in people who have been exposed to someone with the flu[7].
  • Treatment of severe flu complications: In some cases, it may be used to treat influenza-related lower respiratory tract infections in young children[5].

Dosage and Administration

Oseltamivir is typically taken orally in the form of capsules or a liquid suspension. The dosage depends on several factors, including:

  • Age: Different doses are recommended for adults, children, and infants[8].
  • Body weight: In some cases, especially for children, the dose is calculated based on the patient’s weight[3].
  • Kidney function: Patients with reduced kidney function may require lower doses[4].
  • Purpose of use: Different dosages may be prescribed for treatment versus prevention of flu[7].

The standard treatment course for flu is usually 5 days, but this can be extended in severe cases or for certain patient groups[3][8].

Effectiveness

Research has shown that oseltamivir can be effective in:

  • Reducing the duration of flu symptoms: It can shorten the time you feel sick by about 1-2 days if taken early in the course of illness[3].
  • Decreasing viral shedding: This means it can reduce the amount of virus your body releases, potentially making you less contagious[3].
  • Preventing flu complications: It may help reduce the risk of serious complications like pneumonia, especially in high-risk individuals[3].

Side Effects and Safety

Like all medications, oseltamivir can cause side effects. Common side effects may include:

  • Nausea and vomiting
  • Headache
  • Diarrhea
  • Abdominal pain

Serious side effects are rare but can include allergic reactions and neuropsychiatric events. It’s important to discuss any side effects with your healthcare provider[6].

Use in Special Populations

Research is ongoing to understand how oseltamivir can be used safely and effectively in various patient groups:

  • Infants and young children: Studies are investigating appropriate dosing and safety in children under 1 year old[9].
  • Pregnant and breastfeeding women: Research is being conducted to understand how the drug is processed in the body during pregnancy and lactation[2].
  • Obese patients: Studies are examining whether higher doses may be needed for obese individuals[7].
  • Patients with kidney problems: Research is ongoing to determine appropriate dosing for patients with reduced kidney function[4].
  • Immunocompromised patients: Studies are investigating the best dosing strategies for patients with weakened immune systems[8].

Ongoing Research

Scientists continue to study oseltamivir to improve its use and effectiveness. Current areas of research include:

  • New formulations: Researchers are studying intravenous forms of oseltamivir for patients who can’t take oral medications[6].
  • Resistance monitoring: Ongoing studies track the development of oseltamivir-resistant flu strains[3].
  • Combination therapies: Some research is exploring whether combining oseltamivir with other antiviral drugs could be more effective[3].
  • Access and timing: Studies are looking at ways to get patients access to oseltamivir more quickly when they develop flu symptoms[10].
Study Population Key Findings Implications
Children under 2 years Weight-based dosing of 3 mg/kg twice daily was evaluated for safety and efficacy Provides data to support appropriate dosing in very young children
Obese adults Pharmacokinetics of standard 75 mg dose assessed in morbidly obese subjects Helps determine if dose adjustments are needed based on body weight
Immunocompromised children Compared standard vs. triple dose for pharmacokinetics and viral clearance Informs optimal dosing strategies for high-risk pediatric patients
Breastfeeding women Examined oseltamivir concentrations in breast milk and maternal blood Provides data on potential exposure to infants during maternal treatment
Patients with renal impairment Evaluated pharmacokinetics and safety of adjusted doses Guides appropriate dosing for patients with reduced kidney function

FAQ

  • What is oseltamivir and how does it work? Oseltamivir (brand name Tamiflu) is an antiviral medication used to treat and prevent influenza A and B. It works by blocking the action of neuraminidase, an enzyme the flu virus needs to spread within the body.
  • What populations were studied in these clinical trials? The trials examined oseltamivir use in diverse populations including healthy adults, children under 2 years old, obese adults, immunocompromised children, breastfeeding women, and patients with renal impairment.
  • What were some key outcomes measured in the trials? Key outcomes included pharmacokinetics (how the drug moves through the body), viral clearance and shedding, time to symptom resolution, safety and adverse events, and development of viral resistance.
  • Were any special dosing considerations identified for certain groups? Yes, the trials explored weight-based dosing for children, dose adjustments for patients with renal impairment, and evaluated standard vs. high doses in some populations like immunocompromised children.
  • What were some of the main findings regarding safety? Overall, oseltamivir appeared to be well-tolerated across populations. Trials monitored for adverse events, with special attention to neurological events in young children. No major safety concerns were identified, but ongoing monitoring is important.

Ongoing Clinical Trials on Oseltamivir

  • Study on the Effects of Oseltamivir and Drug Combination for Patients with Pneumonia

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Estonia France Italy The Netherlands Portugal +3

  • Study on the Effects of Baricitinib and Drug Combination for Adults with Severe Community-Acquired Pneumonia, Severe Influenza, or Severe and Moderate COVID-19

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Croatia Czechia Estonia France Germany +7

  • Study of oseltamivir and paracetamol blood levels in critically ill patients with severe influenza requiring mechanical ventilation

    Recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study on the Effects of Dexamethasone and Oseltamivir in Patients with Severe Influenza

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Oseltamivir: An antiviral medication used to treat and prevent influenza A and B, also known by the brand name Tamiflu.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Viral shedding: The release of virus from an infected host, which can be measured to assess the duration of viral infection and potential for transmission.
  • AUC (Area Under the Curve): A measure of the total exposure to a drug over time, used in pharmacokinetic studies to assess drug absorption and elimination.
  • Cmax: The maximum concentration of a drug in the blood after administration, used to assess the peak exposure to the medication.
  • Bioequivalence: The property of two drug products having comparable bioavailability and producing the same therapeutic effect.
  • RT-PCR: Reverse Transcription Polymerase Chain Reaction, a laboratory technique used to detect viral genetic material and assess viral load.
  • Viral resistance: The ability of a virus to continue replicating despite the presence of antiviral medications, often due to genetic mutations.
  • Immunocompromised: Having a weakened immune system, which can make individuals more susceptible to infections and complications.
  • Renal impairment: Reduced kidney function, which can affect how drugs are eliminated from the body and may require dose adjustments.

References

  1. https://clinicaltrials.gov/study/NCT02507648
  2. https://clinicaltrials.gov/study/NCT01130636
  3. https://clinicaltrials.gov/study/NCT01032837
  4. https://clinicaltrials.gov/study/NCT01556633
  5. https://clinicaltrials.gov/study/NCT01546935
  6. https://clinicaltrials.gov/study/NCT01050257
  7. https://clinicaltrials.gov/study/NCT01179919
  8. https://clinicaltrials.gov/study/NCT01715909
  9. https://clinicaltrials.gov/study/NCT00391768
  10. https://clinicaltrials.gov/study/NCT01456234